Thursday 19 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterprise solutionsVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Pipeline & R&D

Can-Fite's oral psoriasis drug nears first independent look at Phase III data

Can-Fite BioPharma says the first 247 patients in its piclidenoson trial have finished treatment, setting up an outside-panel review of interim results in early 2027.

18 Nov 2026 · Can-Fite BioPharma Ltd. CANF · Company news

Can-Fite BioPharma has reached the point in its late-stage psoriasis programme where outsiders will first see how the drug is performing. On 18 November 2026 the company said the 247th patient in the opening group of its Phase III trial of oral piclidenoson had received a last dose, which fixes the dataset for a planned interim review.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Can-Fite BioPharma Ltd. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More Pipeline & R&DAll →